Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats

British Journal of Pharmacology

Volumn 164, Issue 8, 2011, Pages 1949-1958

  Kehr, J ^a   Ichinose, F ^a   Yoshitake, S ^a   Goiny, M ^a   Sievertsson, T ^a   Nyberg, F ^b   Yoshitake, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

3,4 methylenedioxymethamphetamine; 4 methylmethcathinone; 5 HT; cathinones; dopamine; legal highs; microdialysis; phenethylamines; psychostimulants; serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; DNA; DOPAMINE; MONOAMINE; SEROTONIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECORDING; REINFORCEMENT; REWARD; SAMPLING; SEROTONIN BRAIN LEVEL; TOXICOKINETICS; WAKEFULNESS;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; HYDROXYINDOLEACETIC ACID; LOCOMOTION; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 80054792045     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01499.x     Document Type: Article

References (56)

1. Alexander SPH, Mathie A, Peters JA, (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Auclair A, Blanc G, Glowinski J, Tassin JP, (2004). Role of serotonin 2A receptors in the d-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors. J Neurochem 91: 318-326. (Pubitemid 39363431)
3. Baumann MH, Rothman RB, (2009). Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol 88: 257-296.
4. Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA, (2009). Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37: 2163-2170.
5. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB, (2011). In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218-225.
6. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J, (2010a). Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. Drug Test Anal accessed on 29 December 2010 [Epub ahead of print] PMID: 21191917.
7. Brandt SD, Sumnall HR, Measham F, Cole J, (2010b). Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2: 377-382.
8. Brandt SD, Sumnall HR, Measham F, Cole J, (2010c). Second generation mephedrone. The confusing case of NRG-1. BMJ 341: c3564.
9. Brunt TM, Poortman A, Niesink RJ, van den Brink W, (2010). Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol accessed on 8 September 2010 [Epub ahead of print] PMID: 20826554.
10. Bubar MJ, Cunningham KA, (2008). Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog Brain Res 172: 319-346.
11. Cadoni C, Di Chiara G, (2007). Differences in dopamine responsiveness to drugs of abuse in the nucleus accumbens shell and core of Lewis and Fischer 344 rats. J Neurochem 103: 487-499. (Pubitemid 47498031)
12. Carhart-Harris RL, King LA, Nutt DJ, (2011). A web-based survey on mephedrone. Drug Alcohol Depend accessed on 21 March 2011 [Epub ahead of print].
13. Dargan PI, Albert S, Wood DM, (2010). Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 103: 875-879.
14. Debruyne D, Courné MA, Le Boisselier R, Djezzar S, Gérardin M, Boucher A, et al,. (2010). Mephedrone: a designer drug of recent use in France. Therapie 65: 519-524. (French).
15. Di Ciano P, Coury A, Depoortere RY, Egilmez Y, Lane JD, Emmett-Oglesby MW, et al,. (1995). Comparison of changes in extracellular dopamine concentrations in the nucleus accumbens during intravenous self-administration of cocaine or d-amphetamine. Behav Pharmacol 6: 311-322.
16. Dickson AJ, Vorce SP, Levine B, Past MR, (2010). Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 34: 162-168.
17. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, et al,. (2002). Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22: 2873-2884. (Pubitemid 37465836)
18. Europol-EMCDDA Joint report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal. September 2010.
19. Fletcher PJ, Rizos Z, Noble K, Higgins GA, (2011). Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade. Neuropharmacology 61: 468-477.
20. Gudelsky GA, Yamamoto BK, (2008). Actions of 3,4- methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90: 198-207. (Pubitemid 351787346)
21. Gustavsson D, Escher C, (2009). Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance. Lakartidningen 106: 2769-2771.
22. Hutchaleelaha A, Sukbuntherng J, Chow HH, Mayersohn M, (1994). Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. Drug Metab Dispos 22: 406-411. (Pubitemid 24158539)
23. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, et al,. (2010). Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 28: 686-689.
24. Kalix P, (1992). Cathinone, a natural amphetamine. Pharmacol Toxicol 70: 77-86.
25. Kalix P, (1994). Khat, an amphetamine-like stimulant. J Psychoactive Drugs 26: 69-74. (Pubitemid 24116474)
26. Kankaanpää A, Meririnne E, Lillsunde P, Seppälä T, (1998). The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59: 1003-1009. (Pubitemid 28237916)
27. Kehr J, (1999). Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques. Chapter 41. In:, Windhorst U, Johansson H, (eds). Modern Techniques in Neuroscience Research. Springer-Verlag GmbH: Heidelberg, pp. 1149-1198.
28. Kehr J, Yoshitake T, (2006). Monitoring brain chemical signals by microdialysis. In:, Grimes CA, Dickey EC, Pishko MV, (eds). Encyclopedia of Sensors, Vol. 6. American Scientific Publishers: Valencia, CA, pp. 287-312.
29. Koob GF, Volkow ND, (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
30. Kurling S, Kankaanpää A, Seppälä T, (2008). Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of amphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in rats. Behav Brain Res 189: 191-201.
31. Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AG, (2011). A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci Int 206: e93-e95.
32. McNamara S, Stokes S, Coleman N, (2010). Head shop compound abuse amongst attendees of the Drug Treatment Centre Board. Ir Med J 103: 134, 136-137.
33. Meyer MR, Wilhelm J, Peters FT, Maurer HH, (2010). Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397: 1225-1233.
34. Milesi-Hallé A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM, (2005). Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol Appl Pharmacol 209: 203-213. (Pubitemid 41713945)
35. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J, et al,. (1999). Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11: 4419-4432. (Pubitemid 30009274)
36. Nicholson PJ, Quinn MJ, Dodd JD, (2010). Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 96: 2051-2052.
37. Nutt D, King LA, Saulsbury W, Blakemore C, (2007). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369: 1047-1053. (Pubitemid 46436128)
38. O'Shea E, Escobedo I, Orio L, Sanchez V, Navarro M, Green AR, et al,. (2005). Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 30: 1312-1323. (Pubitemid 40848085)
39. Panos JJ, Baker LE, (2010). An in vivo microdialysis assessment of concurrent MDMA and cocaine administration in Sprague-Dawley rats. Psychopharmacology (Berl) 209: 95-102.
40. Paxinos G, Watson C, (2007). The Rat Brain in Sterotaxic Coordinates, 6th edn. Elsevier, Academic Press: Amsterdam.
41. Pehek EA, Schechter MD, Yamamoto BK, (1990). Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo. Neuropharmacology 29: 1171-1176.
42. Regan L, Mitchelson M, Macdonald C, (2010). Mephedrone toxicity in a Scottish emergency department. Emerg Med J accessed on 23 December 2010 [Epub ahead of print] PMID: 21183522.
43. Rivière GJ, Byrnes KA, Gentry WB, Owens SM, (1999). Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291: 1220-1226.
44. Rothman RB, Baumann MH, (2006). Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci 1074: 245-260. (Pubitemid 44532828)
45. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al,. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
46. Schep LJ, Slaughter RJ, Beasley DM, (2010). The clinical toxicology of metamfetamine. Clin Toxicol (Phila) 48: 675-694.
47. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al,. (2011). Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214: 593-602.
48. Shulgin A, Shulgin A, (2007). PiHKAL-Phenethylamines I Have Known and Loved: A Chemical Love Story. Transform Press: Berkeley, CA.
49. Torrance H, Cooper G, (2010). The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202: e62-e63.
50. Wee S, Woolverton WL, (2006). Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol Biochem Behav 84: 337-343. (Pubitemid 44107490)
51. Winstock AR, Marsden J, Mitcheson L, (2010a). What should be done about mephedrone? BMJ 340: c1605.
52. Winstock A, Mitcheson L, Marsden J, (2010b). Mephedrone: still available and twice the price. Lancet 376: 1537.
53. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F, (2011). Mephedrone, new kid for the chop? Addiction 106: 154-161.
54. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, et al,. (2010a). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 48: 924-927.
55. Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ovaska H, et al,. (2010b). Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6: 327-330.
56. Wood DM, Greene SL, Dargan PI, (2011). Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 28: 280-282.